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PreviewsGhrelin—a new player in glucose homeostasis?
The hormone ghrelin regulates secretion of growth hormone and energy homeostasis. Sun et al. (2006), in this issue of Cell
Metabolism, demonstrate that ghrelin inhibits insulin secretion. Deletion of ghrelin increased basal insulin level, enhanced
glucose-stimulated insulin secretion, and improved peripheral insulin sensitivity. These effects were not related to changes
in food intake or weight, suggesting ghrelin has unique actions on key components of glucose homeostasis.Blood glucose is tightly controlled by two
key processes—insulin secretion by pan-
creatic b cells in response to a nutrient
challenge and insulin action on major tar-
get organs, i.e., skeletal muscle, liver,
and adipose tissue (Petersen and Shul-
man, 2006). The most common glucose
disorder, type 2 diabetes, is often associ-
ated with obesity and results from insuffi-
cient insulin production/secretion and
insulin resistance. Antidiabetic drugs
include those that stimulate insulin syn-
thesis and secretion, e.g., sulfonylureas
and meglitinides; insulin sensitizers,
e.g., thiazolidinedines; and biguanides,
e.g., metformin, which decrease glucose
production by the liver. Exenatide, a drug
that mimics the action of the gut hormone
glucagon-like peptide (GLP)-1 and aug-
ments insulin release, was recently ap-
proved for treatment of type 2 diabetes.
When patients fail to respond to these
drugs, insulin treatment is initiated to
avoid diseases of the kidneys, eyes, car-
diovascular and nervous systems.
Ghrelin acts on the growth hormone
secretagogue receptor (GHSR) and was
named for its potent effect in stimulating
growth hormone secretion (reviewed in
Smith et al. [2005]). Subsequent studies
found that ghrelin increased food intake
when injected in the brain or peripherally,
lowered energy expenditure and in-
creased weight. Hence, it was proposed
that ghrelin and GHSR could be targeted
for obesity treatment. However, genetic
manipulation of ghrelin and ghsr has not
always produced the expected leanness
in animals, leading to doubts about their
importance in the physiological control
of energy balance and weight (Sun
et al., 2004; Wortley et al., 2004, 2005;
Zigman et al., 2005). Nonetheless, inter-
est in the biology of ghrelin, in particular
its role in glucose control, has persisted.
The highest expression of ghrelin occurs
in the stomach. Ghrelin-producing cells
are also present in intestine, hypothala-
mus, and pancreatic islet. In the latter,
ghrelin may play a developmental role,
as well as modulate release of insulinCELL METABOLISM 3, 301–307, MAY 2006 ª2and glucagon (reviewed in Smith et al.
[2005]).
Deficiency of the adipocyte hormone
leptin results in hyperphagia, obesity,
and insulin resistance, and a variety of
neuroendocrine deficits, notably hypo-
gonadism. Lepob/ob mice initially main-
tain normal glucose levels by increasing
islet size and insulin levels but eventually
develop diabetes. Studies have shown
that leptin and ghrelin act as mutual an-
tagonists to affect energy homeostasis;
hence, leptin blocks the ability of ghrelin
to increase appetite or vice versa (Baraz-
zoni et al., 2003). In the current issue of
Cell Metabolism, Sun et al. (2006) exam-
ined the interaction between ghrelin and
leptin using a genetic approach. To their
surprise, ablation of ghrelin in leptin-
deficient mice did not reverse hyper-
phagia and obesity. There was slight im-
provement in thermoregulation, but mice
deficient in leptin or both ghrelin and lep-
tin had a rapid drop in temperature when
exposed to cold. The major finding was
a reduction in blood glucose and in-
crease in insulin secretion and action
when ghrelin was deleted. Ghrelin defi-
ciency augmented insulin secretion in
response to glucose load (Figure 1). Im-
portantly, ghrelin deficiency preserved
the early-phase insulin secretion, a fea-
ture that is lost in type 2 diabetes. In con-
trast, acute ghrelin treatment blunted
insulin secretion. Glucose and insulin
tolerance were both increased in the ab-
sence of ghrelin. In order to address the
mechanisms underlying ghrelin’s effect
on peripheral insulin sensitivity, the au-
thors performed a hyperinsulinemic eu-
glycemic clamp study on ghrelin knock-
out mice. The loss of ghrelin increased
insulin’s ability to suppress glucose pro-
duction. In contrast, the rate of glucose
infusion to attain euglycemia and rate of
glucose disposal were significantly in-
creased in the absence of ghrelin, con-
firming improvement in peripheral insulin
sensitivity (Figure 1).
The ability of ghrelin deficiency to
improve glucose homeostasis did not006 ELSEVIER INC.depend on resistin, a hormone associ-
ated with insulin resistance (Steppan
et al., 2001). Resistin was elevated in lep-
tin-deficient mice with or without ghrelin.
Because deletion of uncoupling protein 2
(Ucp2) has previously been shown to
increase insulin secretion and glucose
tolerance in Lepob/ob mice, the authors
examined its regulation in the current
model (Zhang et al., 2001). UCP2 was
drastically suppressed in the pancreas of
ghrelin-deficient mice, consistent with
a role in the observed phenotype. Be-
cause these studies were done in a global
ghrelin knockout, the organs mediating
the dual effects on insulin secretion and
insulin sensitivity are unknown. Ghrelin
could act directly on b cells via paracrine
or endocrine mechanisms (Figure 1).
Likewise, the reasons for improvement
in insulin sensitivity are unknown.
These new data offer insights into how
ghrelin affects key components of glu-
cose homeostasis, i.e.,bcell function and
organ response to insulin. However, the
degree to which muscle and adipose tis-
sue contribute to the increase in ‘‘glucose
disposal’’ is not known. Since the use of
Lepob/ob mice could be confounded by
neuroendocrine and metabolic abnor-
malities due to leptin deficiency, e.g.,
steatosis, the role of ghrelin in glucose
metabolism remains to be tested in other
experimental models of ‘‘common’’
(polygenic) obesity and type 2 diabetes,
e.g., diet-induced obese mice. While
UCP2 is a potential culprit, a causal role
for it in insulin secretion remains to be de-
termined, as does the mechanism
through which ghrelin acts on UCP2 in
various peripheral tissues to regulate glu-
cose metabolism.
Still unanswered is why pharmacologi-
cal treatment with ghrelin increases feed-
ing and weight, while deletion of ghrelin
does not affect these parameters. The re-
sults of this study are in agreement with
Dezaki et al. (2004), who reported ghrelin
administration inhibited glucose-induced
insulin secretion, but neither ghrelin
nor ghrelin antagonists affected insulin301
P R E V I E W SFigure 1. Model for actions of ghrelin on glucose homeostasis
Based on deletion of ghrelin, it appears ghrelin acts on pancreatic b cells to inhibit insulin production and
secretion, possibly by increasing UCP2. Ghrelin also inhibits glucose uptake in muscle and adipose tissue
and stimulates glucose production by the liver. Pharmacological stimulation of appetite by ghrelin was not
supported in this genetic model. Ghrelin did not affect feeding or weight.sensitivity. In contrast, low ghrelin level
inhibited while high levels stimulated in-
sulin from mouse islets (Salehi et al.,
2004). Furthermore, Heijboer et al.
(2006) reported that ghrelin treatment
hampered insulin’s ability to suppress
glucose production and increased glu-
cose disposal, actions opposite to the
current study. These discrepancies may
arise from additional effects of ghrelin
treatment on endogenous ghrelin levels,
glucocorticoids, and various hormones.
Overall, the studies provide compelling
evidence that ghrelin has unique dual
effects on glucose homeostasis, at leastFSH versus estrogen:
bones?
Bone loss after menopause or gonadect
2006) challenges this view by showing th
acts on osteoclasts to activate bone res
FSH, independent of estrogen, causes h
In a provocative paper recently published
in Cell (Sun et al., 2006), Drs. Zaidi and
302in a genetic model. Ghrelin antagonism
may be a new approach for treating type
2 diabetes by increasing insulin secretion
and enhancing peripheral insulin action.
The challenge is to ascertain if these
results in rodents can be translated to
patients.
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